Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
2.870
-0.370 (-11.42%)
Feb 21, 2025, 4:00 PM EST - Market closed
Nexalin Technology Revenue
Nexalin Technology had revenue of $36.03K in the quarter ending September 30, 2024, with 49.43% growth. This brings the company's revenue in the last twelve months to $162.08K, up 26.00% year-over-year. In the year 2023, Nexalin Technology had annual revenue of $110.75K, down -91.62%.
Revenue (ttm)
$162.08K
Revenue Growth
+26.00%
P/S Ratio
147.22
Revenue / Employee
$27,013
Employees
6
Market Cap
36.91M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 110.75K | -1.21M | -91.62% |
Dec 31, 2022 | 1.32M | 1.18M | 817.20% |
Dec 31, 2021 | 144.07K | -98.85K | -40.69% |
Dec 31, 2020 | 242.91K | 35.53K | 17.13% |
Dec 31, 2019 | 207.38K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NXL News
- 4 days ago - Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment - GlobeNewsWire
- 12 days ago - Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition - GlobeNewsWire
- 19 days ago - Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study - GlobeNewsWire
- 4 weeks ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23 - GlobeNewsWire
- 2 months ago - Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic - GlobeNewsWire
- 3 months ago - New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market - GlobeNewsWire
- 4 months ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th - GlobeNewsWire
- 4 months ago - Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements - GlobeNewsWire